Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2011

01-10-2011 | Stanford Multidisciplinary Seminars

Acute Liver Failure in a Pediatric Patient with Disseminated Tuberculosis

Authors: Jane Whitney, Melissa Hurwitz, Amirkaveh Mojtahed, Christine Hwang, Amy Gallo

Published in: Digestive Diseases and Sciences | Issue 10/2011

Login to get access

Excerpt

A seven-year-old male presented to the emergency department of a local hospital with sudden onset of mental status changes and jaundice. He had previously been a healthy child who was born and spent his first years of his life in India. He had normal growth and development. He was fully immunized and had also received the Bacillus Calmette–Guérin (BCG) vaccine. His past and family medical history was unremarkable, with the exception that his mother had been successfully treated for isoniazid (INH)-resistant tuberculosis (TB) three years previously. At that time, the patient had 14 mm of induration after a tuberculin skin test, and he and other members of the household were treated for 9 months with rifampin. His chest X-ray remained normal. He had not been previously hospitalized or had any previous surgery. The patient and his family moved to California’s Central Valley several years before admission, and had not traveled since emigrating. The patient was an only child, and the family lived in a household with several healthy relatives and no pets. He was transferred to Stanford University Medical Center for potential liver transplantation. …
Literature
3.
go back to reference Palusci VJ, O’Hare D, Lawrence RM. Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. Pediatr Infect Dis J. 1995;14:144–148.PubMedCrossRef Palusci VJ, O’Hare D, Lawrence RM. Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. Pediatr Infect Dis J. 1995;14:144–148.PubMedCrossRef
4.
go back to reference Lobato MN, Jereb JA, Starke JR. Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity. Pediatrics. 2008;121:e1723–e1733.CrossRef Lobato MN, Jereb JA, Starke JR. Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity. Pediatrics. 2008;121:e1723–e1733.CrossRef
5.
go back to reference Cibo U, Bassanello M, Vitale A, et al. Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver’s early regeneration after auxiliary partial orthotopic liver transplantation. Transpl Int. 2005;17:713–716.CrossRef Cibo U, Bassanello M, Vitale A, et al. Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver’s early regeneration after auxiliary partial orthotopic liver transplantation. Transpl Int. 2005;17:713–716.CrossRef
6.
go back to reference Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy. Liver Transpl. 2006;12:1427–1430.PubMedCrossRef Idilman R, Ersoz S, Coban S, Kumbasar O, Bozkaya H. Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy. Liver Transpl. 2006;12:1427–1430.PubMedCrossRef
7.
go back to reference Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health. 2009;14:1329–1337.PubMedCrossRef Frydenberg AR, Graham SM. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop Med Int Health. 2009;14:1329–1337.PubMedCrossRef
Metadata
Title
Acute Liver Failure in a Pediatric Patient with Disseminated Tuberculosis
Authors
Jane Whitney
Melissa Hurwitz
Amirkaveh Mojtahed
Christine Hwang
Amy Gallo
Publication date
01-10-2011
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2011
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-011-1776-x

Other articles of this Issue 10/2011

Digestive Diseases and Sciences 10/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine